Page last updated: 2024-12-06

triacetyldithranol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Triacetyldithranol, also known as anthralin, is a synthetic anthraquinone derivative with anti-inflammatory and anti-proliferative properties. It is primarily used in the topical treatment of psoriasis. Its mechanism of action involves inhibiting DNA synthesis, reducing cell division, and modulating immune responses. The synthesis of triacetyldithranol involves a multi-step process starting with the anthraquinone derivative 1,8-dihydroxyanthraquinone. Research into triacetyldithranol focuses on its potential applications in treating various dermatological conditions, including psoriasis, vitiligo, and eczema. It is also being investigated for its potential anticancer activity.'

Cross-References

ID SourceID
PubMed CID27751
CHEMBL ID335263
SCHEMBL ID9119527
MeSH IDM0044676

Synonyms (27)

Synonym
dianthrol triacetate
triacetyldithranol
exolan
brn 2180447
anthralin, triacetate
einecs 240-333-0
1,8,9-triacetoxyanthracene
anthracene, 1,8,9-triacetoxy-
1,8,9-tris(acetyloxy)anthracene
anthralin triacetate
1,8,9-anthracenetriol, triacetate
CHEMBL335263
triacetoxyanthrene
SCHEMBL9119527
(8,9-diacetyloxyanthracen-1-yl) acetate
16203-97-7
unii-5jq8u9u95x
5jq8u9u95x ,
3-06-00-06560 (beilstein handbook reference)
dithranol triacetate [who-dd]
1,8,9-anthracenetriol, 1,8,9-triacetate
dithranol triacetate
1,8,9-triacetoxy-anthracene
anthralin, o,o',o''-tri(acetyl)-
IPWOSICBVUXMML-UHFFFAOYSA-N
DTXSID20167301
Q27262457
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID25771Reducing activity against 2,2-diphenyl-1-picrylhydrazyl with an equimolar amount of the test compound; c = Not reactive1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase.
AID228686Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound)1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase.
AID6885Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (80.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.51 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]